Key Insights

Highlights

Success Rate

40% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 60/100

Termination Rate

16.7%

3 terminated out of 18 trials

Success Rate

40.0%

-46.5% vs benchmark

Late-Stage Pipeline

6%

1 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed with results

Key Signals

2 with results40% success

Data Visualizations

Phase Distribution

15Total
Not Applicable (7)
Early P 1 (2)
P 2 (5)
P 3 (1)

Trial Status

Active Not Recruiting9
Terminated3
Completed2
Withdrawn2
Suspended1
Recruiting1

Trial Success Rate

40.0%

Benchmark: 86.5%

Based on 2 completed trials

Clinical Trials (18)

Showing 18 of 18 trials
NCT03899987Phase 2Active Not Recruiting

Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery

NCT04215029Not ApplicableActive Not Recruiting

Lifestyle Intervention for the Reduction of Prostate Cancer Disparities Among African Americans

NCT04985565Not ApplicableActive Not Recruiting

Neoadjuvant Dietary Intervention in Intermediate Risk Prostate Cancer

NCT04624256Not ApplicableActive Not Recruiting

Germline DNA-Based Radiosensitivity Biomarker Influence on Toxicity Following Prostate Radiotherapy, GARUDA Trial

NCT03575832Not ApplicableActive Not Recruiting

Watchful Living in Improving Quality of Life in Participants With Localized Prostate Cancer on Active Surveillance and Their Partners

NCT05320406Phase 2Active Not Recruiting

RElugolix VErsus LeUprolide Cardiac Trial

NCT04981834Not ApplicableSuspended

Robot-Assisted Radical Prostatectomy With or Without Vesicopexy in Patients With Prostate Cancer

NCT04189770Active Not Recruiting

Lifestyle Behavior Influences Among African American Patients With Stage 0-III Prostate Cancer Survivors and Their Partners

NCT04501913Completed

Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes

NCT04519879Phase 2Active Not Recruiting

White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA

NCT04253483Phase 2Active Not Recruiting

Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer

NCT05852041Early Phase 1Recruiting

rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance

NCT04318028Not ApplicableCompleted

An Investigational Scan (7 Tesla MRI) in Diagnosing Cognitive Impairment in Patients With Non-Metastatic Prostate Cancer

NCT04927559Terminated

Health Literacy in Understanding Radiation Therapy Information in Patients Undergoing Definitive Radiation Therapy

NCT04457245Phase 3Terminated

Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer

NCT04288336Early Phase 1Withdrawn

Daily, Long-Term Intermittent Fasting for the Prevention of PSA-Recurrence in Patients With Localized Prostate Cancer After Radical Prostatectomy

NCT04399824Not ApplicableWithdrawn

Focal Radiation Therapy for the Treatment of Low or Intermediate-Risk Prostate Cancer

NCT03570476Phase 2Terminated

Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer

Showing all 18 trials

Research Network

Activity Timeline